Abalos’ arena: planning to upstage oncolytic viruses

Abalos launches with €12 million series A to advance its arenavirus-based cancer therapies

Abalos launched Tuesday with a €12 million ($13.2 million) series A round to advance its arenavirus-based cancer therapies, which offer an alternative to oncolytic viruses, and rely on prolonged immune responses to clear tumors.

Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr co-led the tranched round with participation from NRW.BANK and High-Tech Gründerfonds.

A spin-off from the University of Duisburg-Essen and the

Read the full 613 word article

User Sign In